- Home
- Publications
- Publication Search
- Publication Details
Title
Poly(
ADP
‐ribose) polymerase inhibition in pancreatic cancer
Authors
Keywords
-
Journal
GENES CHROMOSOMES & CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-12-21
DOI
10.1002/gcc.22932
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
- (2020) Eileen M. O’Reilly et al. JOURNAL OF CLINICAL ONCOLOGY
- Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
- (2020) Michelle Chan-Seng-Yue et al. NATURE GENETICS
- Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer
- (2020) Talia Golan et al. ANNALS OF SURGICAL ONCOLOGY
- BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects
- (2020) Winston Wong et al. Cancer Management and Research
- A Phase I/II Study of Veliparib (ABT-888) in combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer
- (2020) Michael J Pishvaian et al. CLINICAL CANCER RESEARCH
- Pancreatic cancer
- (2020) Jonathan D Mizrahi et al. LANCET
- Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers
- (2020) Timothy A. Yap et al. Cancer Discovery
- Inhibition of RAS: proven and potential vulnerabilities
- (2020) Mariyam Zuberi et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Challenges and Opportunities for Pancreatic Cancer Immunotherapy
- (2020) Adham S. Bear et al. CANCER CELL
- Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer
- (2020) Stephan B. Dreyer et al. GASTROENTEROLOGY
- Poly(ADP-ribose) polymerase inhibition: past, present and future
- (2020) Nicola J. Curtin et al. NATURE REVIEWS DRUG DISCOVERY
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploring and comparing adverse events between PARP inhibitors
- (2019) Christopher J LaFargue et al. LANCET ONCOLOGY
- A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
- (2019) R. Tuli et al. EBioMedicine
- Chemotherapy for pancreatic cancer
- (2019) Christoph Springfeld et al. PRESSE MEDICALE
- Molecular subtypes of pancreatic cancer
- (2019) Eric A. Collisson et al. Nature Reviews Gastroenterology & Hepatology
- Real-time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations that Might be Targeted with Existing Drugs or Used as Biomarkers
- (2019) Aatur D. Singhi et al. GASTROENTEROLOGY
- Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513.
- (2019) E. Gabriela Chiorean et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy.
- (2019) Kim Anna Reiss et al. JOURNAL OF CLINICAL ONCOLOGY
- Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial.
- (2019) Anup Kasi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
- (2019) Alanna R. Kaplan et al. Science Translational Medicine
- A decade of clinical development of PARP inhibitors in perspective
- (2019) J Mateo et al. ANNALS OF ONCOLOGY
- Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
- (2019) Yong Fang et al. CANCER CELL
- Tumour lineage shapes BRCA-mediated phenotypes
- (2019) Philip Jonsson et al. NATURE
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Defining and Modulating ‘BRCAness’
- (2019) Andrea K. Byrum et al. TRENDS IN CELL BIOLOGY
- Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
- (2019) P Hammel et al. ANNALS OF ONCOLOGY
- PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
- (2019) Sylvie M. Noordermeer et al. TRENDS IN CELL BIOLOGY
- Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer
- (2019) Gayle S. Jameson et al. JAMA Oncology
- Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer
- (2019) Maeve A. Lowery BRITISH JOURNAL OF CANCER
- A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
- (2018) Jordan Berlin et al. BRITISH JOURNAL OF CANCER
- Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma
- (2018) Eileen M. O'Reilly et al. CANCER
- Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
- (2018) Maeve A. Lowery et al. EUROPEAN JOURNAL OF CANCER
- Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer
- (2018) Chunling Hu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Biomarkers for Homologous Recombination Deficiency in Cancer
- (2018) Michal M Hoppe et al. JNCI-Journal of the National Cancer Institute
- Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
- (2018) Maeve A Lowery et al. JNCI-Journal of the National Cancer Institute
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- NRG1 Fusions in KRAS Wild-type Pancreatic Cancer
- (2018) Christoph Heining et al. Cancer Discovery
- Biomarkers for Homologous Recombination Deficiency in Cancer
- (2018) Michal M Hoppe et al. JNCI-Journal of the National Cancer Institute
- Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
- (2018) Maeve A Lowery et al. JNCI-Journal of the National Cancer Institute
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes
- (2018) Sebastian Mueller et al. NATURE
- Development of PARP and Immune-Checkpoint Inhibitor Combinations
- (2018) Ross A Stewart et al. CANCER RESEARCH
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypermutation In Pancreatic Cancer
- (2017) Jeremy L. Humphris et al. GASTROENTEROLOGY
- Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma
- (2017) Koji Shindo et al. JOURNAL OF CLINICAL ONCOLOGY
- A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress
- (2017) Peter M Bruno et al. NATURE MEDICINE
- Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer
- (2017) Grainne M. O’Kane et al. TRENDS IN MOLECULAR MEDICINE
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma
- (2017) Ashton A. Connor et al. JAMA Oncology
- Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
- (2015) J. Bendell et al. ANNALS OF ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study
- (2015) Manuela Quaresma et al. LANCET
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- High Prevalence of BRCA1 and BRCA2 Germline Mutations with Loss of Heterozygosity in a Series of Resected Pancreatic Adenocarcinoma and Other Neoplastic Lesions
- (2013) A. L. Lucas et al. CLINICAL CANCER RESEARCH
- Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
- (2013) Nasim Mavaddat et al. JNCI-Journal of the National Cancer Institute
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature
- (2009) Edward James et al. ANTI-CANCER DRUGS
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRCAGermline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
- (2008) Cristina R. Ferrone et al. JOURNAL OF CLINICAL ONCOLOGY
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation